Table 3.

Some recent noteworthy clinical trials of Hsp70-driven medications in NDDs.

Medication	Model for trial	Results	References
Arimoclomol	Adults diagnosed with probable/definite ALS	Controversial results; no data about benefits in finals with good intermediate endpoints passing as for Year 2016	NCT03491462; NCT00706147; NCT00244244 (Kalmar and Greensmith, 2017)
Arimoclomol	Patients of 2–18 years with NPC	Arimoclomol showed a 65% retardation of annual disease progression	NCT02612129 (Mengel et al., 2021)
Colchicine + riluzole	Adults diagnosed with probable/definite ALS	Ongoing	NCT03693781 (Mandrioli et al., 2019)
J147	Healthy subjects (Phase I only)	No results found yet to be posted	NCT03838185
Leucomethylene blue dimesylate	Adults with diagnosis of all cause dementia and probable AD	Results revealed no benefit of the medication to treat patients with mild to moderate AD	NCT01689246 (Gauthier et al., 2016)
Phenlarmide	Parkinson’s disease	No results found yet to be posted	NCT04693039; NCT04164121
Pioglitazone + riluzole	Adults diagnosed with probable/definite ALS	A clinical improvement was shown with no distinct role of Hsp70 elucidated although it is theorized	NCT00690118, NCT00919555 (Dupuis et al., 2012)
Riluzole	Adults diagnosed with probable/definite ALS	Riluzole 100 mg daily was found prone to improve median survival by 2–3 months	Several trials with similar results; we mention the most detailed one [a retrospective integration of results by Miller et al. (2012)]

We included clinical trials that are already completed independently of the fact if the results have been or not been published yet as well as ongoing searches for tag combinations of “Hsp70” with “neurodegeneration,” “neurodegenerative,” “AD,” “PD,” “HD,” “ALS,” “FTD” in all free and open accessible databases.